Sentinel-Lymphknoten – Der positive Sentinel – mit und ohne Konsequenz?

• Literatur

• 1 Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 1989; 63 (Suppl. 01) 181-187
• 2 Straver ME, Meijnen P, Tienhoven G et al. Role of axillary clearance after a tumor-positive sentinel node in the administration of adjuvant therapy in early breast cancer. J Clin Oncol 2010; 28 (Suppl. 05) 731-737
• 3 Taras AR, Hendrickson NA, Lower KA et al. Recurrence rates in breast cancer patients with false-negative intraoperative evaluation of sentinel lymph nodes. Am J Surg 2010; 199 (Suppl. 05) 625-628
• 4 Giuliano LMM AE, Beitsch PD, Whitworth PW et al. ACOSOG Z0011: A randomized trial of axillary node dissection in women with clinical T1-2 N0 M0 breast cancer who have a positive sentinel node. J Clin Oncol 28 18s, 2010; (suppl; abstr CRA506) 2010;
• 5 Orr RK. The impact of prophylactic axillary node dissection on breast cancer survival – a Bayesian meta-analysis. Ann Surg Oncol 1999; 6 (Suppl. 01) 109-116
• 6 Albain KS, Barlow WE, Shak S et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol 2010; 11 (Suppl. 01) 55-65
• 7 Hirata T, Shimizu C, Yonemori K et al. Change in the hormone receptor status following administration of neoadjuvant chemotherapy and its impact on the long-term outcome in patients with primary breast cancer. Br J Cancer 2009; 10 (Suppl. 09) 1529-1536
• 8 Jang JY, Jeon YK, Kim CW. Degradation of HER2/neu by ANT2 shRNA suppresses migration and invasiveness of breast cancer cells. BMC Cancer 2010; 10: 391
• 9 Ashikaga T, Krag DN, Land SR et al. Morbidity results from the NSABP B-32 trial comparing sentinel lymph node dissection versus axillary dissection. J Surg Oncol 2010; 102 (Suppl. 02) 111-118